The cost of precision medicine is quite high, and it costs about $100,000 a year for treatment. In most cases, such a cost can only be exchanged for the patient's life for a few months.

Accurate medical care is accompanied by accurate medical plans in the United States, China and the United Kingdom, attracting capital competition. This technology, based on a person's genes, lifestyles and environment, can be used to develop a medical plan. If successful, doctors can hope to choose the most effective treatment for their condition based on their genomic and physiological functions.

The data shows that up to now, there are 854 companies in China's precision medical care, which does not include projects being brewed in the laboratories of universities and research institutes. Sequoia Capital, Huiqiao Capital, Honghui Capital, these well-known investment institutions in the venture capital circle are all increasing the layout of the precision medical industry chain, from liquid biopsy, gene editing, to gene big data, and immune cells. Treatment is all-encompassing, and the industry's popularity is evident.

Despite this, this claim will bring about a new technological revolution in medical technology innovation, and there is still a long way to go before clinical applications. Ying Mingang, dean of the Fujian Cancer Hospital, mentioned in a recent future forum on precision medicine that there are not many diseases that can be treated in clinical applications with the results of precision medical research. New concepts such as gene sequencing , key gene screening, and personalized medicine have not been widely used in clinical practice. Surgery and chemotherapy are still the mainstream.

Hot capital market

At present, many investment institutions are very optimistic about the genetic diagnosis companies such as WuXi PharmaTech, Huada and Burning Stone, and they have invested in them, such as Sequoia Capital. In their view, not only technological innovation is the only investment standard, but if the domestic precision medical company has strong ability to land, it has sufficient capacity in government relations, commercial channels, patient education, etc., and can become the leading enterprise in the industry. . In addition to genetic testing, Sequoia has also invested in Beida Pharmaceuticals in precision treatment.

The current situation is that investment institutions such as Sequoia have investments at home and abroad. Their requirements for Chinese companies are often equal to technical and commercial capabilities and government relations, while overseas companies only invest in technology-leading assets.

BGI is a genetic sequencing company that leads China and the world. Six years ago, the Shenzhen-based company had just purchased 128 of the world's fastest genetic sequencers, allegedly possessing more than half of the world's DNA decoding capabilities. But with Wang Jun, the main talent scientist who left in July last year, the machine he purchased was outdated, and his own industrial-grade whole-genome sequencer also encountered obstacles in November last year. BGI has also had to spend more on the next generation of sequencing instruments.

Gene sequencing is an important part of precision medicine and a part of achieving accurate diagnosis. The goal of sequencing companies is to turn rich genomic data into medical advantages. But China's genetic sequencing is still at the stage of providing sequencing services or providing data analysis reports. Upstream machine manufacturing is dominated by European and American leading companies such as Illumina and LifeTech. Illumina, the world's largest upstream genetic sequencer manufacturer, accounts for 71% of the global market. At present, gene sequencing equipment and consumables are the most profitable part of the industry chain, with a gross margin of 70%.

Injectable Anti Acne Solution

Injectable Anti Acne Solution,Acne Mesotherapy Solution,Anti Acne Meso Solution,Acne Treatment Mesotherapy

Jiangsu Tiera Biotechnology Co., Ltd , https://www.tierabio.com